Question 1

What is KTP-001?

Accepted Answer

KTP-001 is a Other.

Question 2

How often does KTP-001 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was KTP-001 first tracked by Ergen?

Accepted Answer

First tracked on May 26, 2026.

Question 4

When was KTP-001 last mentioned in news?

Accepted Answer

Last active on May 26, 2026.

Question 5

What is KTP-001's current news sentiment?

Accepted Answer

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is KTP-001 in global news coverage?

Accepted Answer

Attention score of 3, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving KTP-001?

Accepted Answer

AGC Biologics to manufacture Teikoku Seiyaku's KTP-001 (May 26, 2026, 6 articles).

Question 8

How did the "AGC Biologics to manufacture Teikoku Seiyaku's KTP-001" event impact KTP-001?

Accepted Answer

KTP-001 is a recombinant human matrix metalloproteinase-7 (rhMMP-7) drug substance being developed to treat lumbar disc herniation, representing a potential new therapy in the pharmaceutical market.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.